Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -115.58% | -109.01% | 131.62% | 99.73% | 72.45% |
| Total Depreciation and Amortization | 14.34% | 20.07% | 28.19% | 28.68% | 29.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.83% | 48.74% | 83.92% | 88.79% | 27.62% |
| Change in Net Operating Assets | 51.33% | -0.91% | -354.48% | -172.68% | -63.01% |
| Cash from Operations | -370.34% | -159.37% | 169.07% | 138.79% | 106.21% |
| Capital Expenditure | 59.32% | 71.74% | 78.47% | 83.98% | 78.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.87% | -35.79% | 35.10% | 61.73% | -2,767.47% |
| Cash from Investing | -88.71% | -25.88% | 43.64% | 69.22% | -154.94% |
| Total Debt Issued | 76.19% | 81.19% | -97.38% | -97.38% | -- |
| Total Debt Repaid | 41.53% | 11.29% | -- | -- | -- |
| Issuance of Common Stock | -10.49% | -22.92% | -31.33% | -43.16% | -43.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -221.33% | -134.14% | -100.00% | -57.33% | -66.27% |
| Cash from Financing | 70.69% | 34.29% | -95.66% | -91.50% | -4.73% |
| Foreign Exchange rate Adjustments | -60.70% | -67.83% | -105.58% | -109.55% | 28,178.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.24% | -95.16% | 3,515.49% | 1,609.42% | 268.06% |